These screening efforts resulted in the identification of various IPC compounds possessing anti-infl...

1. Dermalogix awarded SBIR Phase II grant to develop topical
drug candidate for atopic dermatitis
These screening efforts resulted in the identification of various IPC compounds possessing antiinflammatory and also anti-microbial activity. ("Dermalogix") announced these days the National
Institute involving Arthritis as well as Musculoskeletal and Skin Diseases (NIAMS) awarded the
business a new Little business Innovation Study (SBIR) Stage II grant totaling $1.6 million for your
development of your topical drug candidate pertaining to atopic dermatitis.
Dermalogix awarded SBIR Cycle II grant in order to develop topical drug candidate for atopic
dermatitis "This award is actually further validation of the chance of IPC compounds in dermatology.
Dr. Eduardo Perez, VP of R&D and also business Development stated, "Building around the expertise
and also momentum provided by SIG990, we believe effective development in our novel class
regarding topical IPC compounds will offer an essential additional, and potentially better,
therapeutic alternative for people suffering atopic dermatitis."
Signum Dermalogix, Inc. Recently, together with National Institute regarding Allergy along with
Infectious Diseases (NIAID) SBIR funding, Dermalogix announced that the Investigational New Drug
(IND) Application to judge IPC compound SIG990 throughout rosacea continues in order to be
cleared from the FDA.
SOURCE Signum Dermalogix, Inc. Dermalogix features a successful monitor record inside receiving
and executing in NIH funding. We are pleased to be awarded this grant through the NIH along with
our objective continues to become the actual development in our technology with the objective of
delivering therapeutic agents for you to treat skin disease," stated Maxwell Stock, President & CEO.
Utilizing your funding provided with almost all the earlier Stage I grant, Dermalogix set up a new
novel screening paradigm in order to effectively identify potent therapeutic compounds through its
isoprenylcysteine (IPC) technology platform. This particular Cycle II funding will most likely be used
to select a lead drug candidate along with commence IND-enabling safety/toxicology studies.